Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled alpha-1 antitrypsin for alpha-1 antitrypsin deficiency with emphysema
2008-005326-36Phase 2Completed
- Sponsor
- Kamada Ltd.
- Start
- Aug 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) and emphysema comparing Aerosolized human alpha-1 antitrypsin with Placebo (2 arms). Primary endpoint: Time to first moderate or severe event-based exacerbation. Started Aug 2009; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2008-005326-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005326-36.